Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid for Prevention of ART-Induced Bone Loss in HIV
NCT06762730Phase 4Recruiting
- Sponsor
- Hadassah Medical Organization
- Start
- Dec 2024
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of zoledronic acid in osteopenia (4 arms), sponsored by Hadassah Medical Organization. Primary endpoint: Bone density at 12 months. Started Dec 2024; status: recruiting.
02
Drugs
zoledronic acid
03
Conditions
osteopenia
Beyond the preview
Go deeper on NCT06762730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06762730.